Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 19/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 17/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 16/20 | 0.52 |
| ▸ | TSHR | P16473 | 12/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 13/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2124675 | 1.00 | CYP3A4 (0.52) | CYP3A4CYP2C9CYP2C19TSHRALDH1A1 | |
| SCHEMBL2605314 | 0.88 | SYK (0.47) | CYP3A4CYP2C9CYP2C19TSHRALDH1A1 | |
| SCHEMBL3711814 | 0.87 | CYP3A4 (0.54) | CYP3A4CYP2C9CYP2C19TSHRALDH1A1 | |
| SCHEMBL2605318 | 0.83 | SLC6A9 (0.60) | CYP3A4CYP2C9CYP2C19TSHRALDH1A1 | |
| SCHEMBL30191495 | 0.80 | CTSL (0.45) | ALDH1A1MEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL2605309 | 0.80 | SLC6A9 (0.68) | — | |
| SCHEMBL2126423 | 0.77 | SLC6A9 (0.39) | TSHRALDH1A1KMT2AMAPK1MAPT | |
| SCHEMBL2125188 | 0.77 | SLC6A9 (0.39) | TSHRALDH1A1KMT2AMAPK1MAPT | |
| SCHEMBL2126165 | 0.77 | SLC6A9 (0.39) | TSHRALDH1A1KMT2AMAPK1MAPT | |
| SCHEMBL25364651 | 0.76 | HTR2C (0.43) | KMT2ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | US | disclosed |
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | US | disclosed |
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | US | disclosed |
| WO-2010087762-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | SLC1A2, B4GALT1, SLC6A1 | CYP3A4 838/4885CYP2C9 946/4885CYP2C19 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.